No abstract available.
Plasminogen Activators* ; Plasminogen*

No abstract available.
Plasminogen Activators* ; Plasminogen* ; Pulmonary Embolism*

PURPOSE: We investigated coagulation disorders in Korean patients of idiopathic avascular necrosis of the femoral head. MATERIALS AND METHODS: Ten laboratory parameters related with coagulation pathway were measured and analyzed in fifty-three patients with idiopathic avascular necrosis of the femoral head and compared the results with those of thirty-one healthy persons. RESULTS: Differences in the values of plasminogen activator inhibitor and D-dimer in the two groups were statistically significant (p<0.05). The number of three or four abnormal parameters in the patient group was nearly twice that of the control. Hypofibrinolytic activity, determined by increased plasminogen activator inhibitor and lipoprotein(a), were observed in eleven cases (20.8%) of the patient group. CONCLUSION: The abnormal results that were observed in the patient group may contribute to the predisposition of thrombotic venous occlusion in the head of the femur, leading to avascular necrosis of the femoral head.
Femur ; Head* ; Humans ; Lipoprotein(a) ; Necrosis* ; Plasminogen Activators

No abstract available.
Humans ; Intracranial Hemorrhages* ; Plasminogen Activators* ; Plasminogen* ; Rivaroxaban* ; Thrombolytic Therapy

There is increasing evidence that thrombin is directly involved in the pathogenesis of cerebral edema after intracerebral hemorrhage. Some authors emphasize that early removal of hematoma using plasminogen activator can be an effective intervention that interrupts the cascade of events leading to increasing edema formation and white matter injury. Recently, there are many reports of the edema intensification following plasminogen activator-induced lysis of the intracerebral clot. The author reports a case who showed protracted perihematomal edema after hematoma evacuation and fibrinolysis therapy with urokinase. Considering that the benefit obtained from fibrinolysis therapy may be offset by an accentuation of its toxic edematous effect, further investigation into the use of urokinase for hematoma evacuation should be undertaken.
Brain Edema ; Cerebral Hemorrhage ; Edema* ; Fibrinolysis* ; Hematoma ; Plasminogen ; Plasminogen Activators ; Thrombin ; Urokinase-Type Plasminogen Activator*

BACKGROUND: There are evidences that uPA and its inhibitor play a key role in tumor spread. We studied whether uPA and PAI-1 expressions could serve as prognostic parameters along with clinical, gross and microscopic findings in gallbladder carcinomas. METHODS: We analyzed 42 cases of gallbladder carcinomas by immunohistochemical staining and clinicopathologic parameters. RESULTS: uPA and PAI-1 were more frequently expressed in the adenocarcinoma than in the normal or benign gallbladder tissue. The uPA expression in the glands of low grade adenocarcinoma was significantly correlated with both distant and lymph node metastases. The uPA expression in the stroma around the low grade adenocarcinoma was significantly correlated with either distant or lymph node metastasis. The PAI-1 expression was significantly correlated with lymph node metastasis only for both distant and lymph node metastases. In multivariate analysis, the lymphatic invasion was significantly related to poor survival (p= 0.0115). In univariate analysis, the cases without lymphatic invasion had prolonged survival. Positive expression of uPA in the glands of low-grade adenocarcinoma was significantly correlated with poor survival (p=0.0391). CONCLUSION: In conjunction with clinicopathologic findings, expressions of uPA and PAI-1 may be useful prognostic markers in gallbladder carcinomas.
Adenocarcinoma ; Gallbladder* ; Lymph Nodes ; Multivariate Analysis ; Neoplasm Metastasis ; Plasminogen Activator Inhibitor 1 ; Plasminogen Activators* ; Plasminogen* ; Prognosis ; Urokinase-Type Plasminogen Activator*

To examine the relationship between plasma plasminogen activator inhibitor-1[PAI-1]antigen concentration and diabetic retinopathy in non-insulin dependent diabetic patients, PAI-1 antigen levels and some fibri-nolytic parameters were studied in 89 non-insulin dependent diabetic patients[mean age 59.8 +/-11.3 years]and 25 normal adults as control[meanage 52.8 +/-14.7 years]. The diabetic patients were classified as three subgroups: no DR[n=34], NPDR[n=29]and PDR[n=26]according to the degree of retinopathy.The PAI-1 antigen concentration was measured by enzyme immunoassay[Innotest PAI Ag kit].The diabetic patients had a significantly higher mean PAI-1 antigen level [34.56 +/-17.80ng/milliliter ]compared to a control group[20.35 +/-15.78 ng/milliliter ][p<0.05].Plasma PAI-1 antigen level was significantly lower in diabetic patients with PDR[27.39 +/-15.54 ng/milliliter ]than in diabetics with no DR[36.87 +/-23.31 ng /milliliter ]or NPDR[39.43 +/-2 0.17 ng/milliliter ][p<0.05], probably because of more extensive systemic endothelial damage. These results support the hypothesis that impaired fibrinolysis due to elevated PAI-1 is associated with the development of retinopathy, and therefore the levels of PAI-1 can be used as useful indicator for the development and progression of proliferative retinopathy.
Adult ; Diabetes Mellitus, Type 2* ; Diabetic Retinopathy* ; Fibrinolysis ; Humans ; Plasma* ; Plasminogen Activator Inhibitor 1* ; Plasminogen Activators

The cornerstone of acute ischemic stroke treatment relies on rapid clearance of an offending thrombus in the cerebrovascular system. There are various drugs and different methods of assessment to select patients more likely to respond to treatment. Current clinical guidelines recommend the administration of intravenous alteplase (following a brain noncontract CT to exclude hemorrhage) within 4.5 hours of stroke onset. Because of the short therapeutic time window, the risk of hemorrhage, and relatively limited efficacy of alteplase for large clot burden, research is ongoing to find more effective and safer reperfusion therapy, as well as focussing on refinement of patient selection for acute reperfusion treatment. Studies using advanced imaging (incorporating perfusion CT or diffusion/perfusion MRI) may allow us to use thrombolytics, or possibly endovascular therapy, in an extended time window. Recent clinical trials have suggested that Tenecteplase, used in conjunction with advanced imaging selection, resulted in more effective reperfusion than alteplase, which translated into increased clinical benefit. Studies using Desmoteplase have suggested its potential benefit in a sub-group of patients with large artery occlusion and salveageable tissue, in an extended time window. Other ways to improve acute reperfusion approaches are being actively explored, including endovascular therapy, and the enhancement of thrombolysis by ultrasound insonation of the clot (sono-thrombolysis).
Arteries ; Brain ; Hemorrhage ; Humans ; Patient Selection ; Perfusion ; Plasminogen Activators ; Reperfusion ; Stroke ; Thrombosis ; Tissue Plasminogen Activator

Plasmin is an enzyme which plays an important role in the inflammatory process by activating vasoactive amine and lysis of fibrin. On the other hand, plasmin is also known to activate latent collagenase. Plasmin is an activated form of plasminogen which is stimulated by the plasminogen activator that exists in plasma and tissue. Gordon et al(1980) insisted that collagenase is important to the formation of corneal ulcer because it destroys the collagen which is the main component of the cornea. Berman et al(1980) reported that corneal tissue destruction by plasminogen activator-plasmin system can be a cause of corneal ulcer. We could obtain the following results by checking the plasmin activity in the tear of chronic corneal ulcer patients and necrotizing scleritis patients. 1. The plasmin activity in the tear was increased in all three chronic corneal ulcer patients in concentration of 1/16 sigma unit/ml to 1/8 sigma unit/ml. 2. There was no plasmin activity in the tear of the two necrotizing scleritis patients.
Collagen ; Collagenases ; Cornea ; Corneal Ulcer* ; Fibrin ; Fibrinolysin* ; Hand ; Humans ; Plasma ; Plasminogen ; Plasminogen Activators ; Scleritis ; Tears*

Plasminogen activator(PA) and plasminogen activator inhibitor(PAI) are involved in many physiological or pathological events. The Sertoli cells, the important elements within the seminiferous epithelium, are thought to play a key role in spermatogenesis. The Sertoli cells secrete PA and PAI. The levels of them are modulated by hormonal and cell-mediated influences. They play a fundamental role in the maintenance of spermatogenesis, sperm motility and fertilization.
Humans ; Male ; Plasminogen Activators ; metabolism ; physiology ; Plasminogen Inactivators ; metabolism ; physiology ; Sertoli Cells ; metabolism ; physiology ; Testis ; cytology